AbCellera Biologics Inc. (ABCL)
Automate Your Wheel Strategy on ABCL
With Tiblio's Option Bot, you can configure your own wheel strategy including ABCL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABCL
- Rev/Share 0.0776
- Book/Share 1.1199
- PB 1.1058
- Debt/Equity 0.0618
- CurrentRatio 10.1461
- ROIC -0.5774
- MktCap 1134243000.0
- FreeCF/Share -0.4786
- PFCF -7.9611
- PE -6.7388
- Debt/Assets 0.1091
- DivYield 0
- ROE -0.1573
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABCL | The Benchmark Company | Buy | Hold | -- | -- | Aug. 20, 2024 |
News
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
Published: June 02, 2025 by: The Motley Fool
Sentiment: Positive
Investors were surely discovering drug discovery company AbCellera Biologics (ABCL 6.19%) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day.
Read More
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
Published: May 30, 2025 by: Business Wire
Sentiment: Neutral
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.
Read More
AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Jacqueline Kisa - TD Securities Puneet Souda - Leerink Partners LLC Malcolm Hoffman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Good afternoon, and welcome to AbCellera's First Quarter 2025 Business Update and Conference Call. My name is Jasmine, and I will facilitate the audio portion of today's interactive broadcast.
Read More
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.
Read More
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Steve Dechert - KeyBanc Jacqueline Kisa - TD Securities Malcolm Hoffman - BMO Capital Markets Operator Good afternoon and welcome to AbCellera's Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today's interactive broadcast.
Read More
About AbCellera Biologics Inc. (ABCL)
- IPO Date 2020-12-11
- Website https://www.abcellera.com
- Industry Biotechnology
- CEO Carl L.G. Hansen
- Employees 596